<DOC>
	<DOCNO>NCT01728155</DOCNO>
	<brief_summary>The European study , LINES 2009 ( Low Intermediate Risk Neuroblastoma European Study ) , group together single protocol treatment patient `` non high risk '' neuroblastoma ( NB ) , stratification two group : low risk intermediate risk . These two separate cohort include one single protocol enable patient data two group enter common database , current prognostic classification determine treatment may evolve subsequent detailed molecular analysis tumour . 1 . LOW RISK STUDY The Low Risk Study propose order : - minimise amount treatment ( chemotherapy surgery ) appropriate low risk patient , previous study show excellent long-term outcome ( SIOPEN 99.1-2 infant neuroblastoma study overall survival great 97 % ( H. Rubie , JCO ) . - improve EFS maintain OS ( overall survival ) L2 Ms patient SCA ( Segmental Cromosomal Aberration ) genomic profile tumour ( presence segmental chromosomal change ( SCA ) ) electively treat patient chemotherapy despite absence symptom . 2 ) INTERMEDIATE RISK STUDY The Intermediate Risk Study propose order : - reduce amount chemotherapy differentiate histology INRG ( International Neuroblastoma Risk Group ) stage L2 NB ganglioneuroblastoma nodular patient previous SIOPEN study show excellent long-term outcome ; - increase amount treatment ( radiotherapy 13-cis-RA ( 13-cis-Retinoic Acid ) poorly differentiate undifferentiated histology INRG stage L2 NB ganglioneuroblastoma nodular patient order improve EFS register previous SIOPEN study ; - improve EFS ( Event Free Survival ) MYCN ( V-Myc myelocytomatosis viral relate oncogene , NB derive , avian ) amplify INSS ( International NB Staging System ) stage 1 NB patient introduction adjuvant treatment ; - maintain good result obtain previous SIOPEN study INRG stage M infant moderate treatment . NEONATAL SUPRARENAL MASSES The incidence suprarenal tumours/masses increase last decade due expand use prenatal ultrasonography routine obstetric care neonatal early infancy care . The differential diagnosis mass range benign ( adrenal haemorrhage ) malignant process ( neuroblastoma , adrenal carcinoma ) . Knowledge perinatal suprarenal mass , although base relatively large literature , scatter amongst study case methodical approach often short follow . Therefore , optimal management mass clearly define . Neuroblastoma age intriguing entity good prognosis case . The SIOPEN Group , base result first multicenter European Trial infant neuroblastoma ( INES ) world-wide experience provide literature , launch European surveillance study ( Multi-centre , non-blinded , one arm prospective trial ) mass . Treatment : Observation</brief_summary>
	<brief_title>European Low Intermediate Risk Neuroblastoma Protocol</brief_title>
	<detailed_description>1 . LOW RISK STUDY The low risk group patient include NB patient without MYCN amplification without life threaten symptom follow clinical situation : - Children age ≤ 18 month localise neuroblastoma associate image define risk factor preclude upfront surgery ( stage INRG L2 ) . - Children age ≤ 12 month disseminate neuroblastoma without bone , pleura , lung CNS ( Central Nervous System ) disease ( stage INRG Ms ) 2 ) INTERMEDIATE RISK STUDY The intermediate risk group patient include NB patient follow clinical situation : - Children age &gt; 18 month localise neuroblastoma without MYCN amplification , associate image define risk factor preclude upfront surgery ( stage INRG L2 ) . - Children age ≤12 month disseminate neuroblastoma involve bone , pleura , lung and/or CNS ( stage INRG M ) , without MYCN amplification . - Children localise resect NB ( stage INSS I ) MYCN amplification . NEONATAL SUPRARENAL MASSES The incidence suprarenal tumours/masses increase last decade due expand use prenatal ultrasonography routine obstetric care neonatal early infancy care . The differential diagnosis mass range benign ( adrenal haemorrhage ) malignant process ( neuroblastoma , adrenal carcinoma ) . Knowledge perinatal suprarenal mass , although base relatively large literature , scatter amongst study case methodical approach often short follow . Therefore , optimal management mass clearly define . Neuroblastoma age intriguing entity good prognosis case . The SIOPEN Group , base result first multicenter European Trial infant neuroblastoma ( INES ) world-wide experience provide literature , launch European surveillance study ( Multi-centre , non-blinded , one arm prospective trial ) mass . Treatment : Observation</detailed_description>
	<mesh_term>Neuroblastoma</mesh_term>
	<criteria>1 . LOW RISK STUDY Inclusion criterion whole low risk group : inform consent followup warrant ; group assignment complete within 6 week diagnosis ; prior chemotherapy radiotherapy Biopsy proven neuroblastoma Tumour genomic profile obtain NRL accord guideline MYCN nonamplified Exclusion criterion whole low risk group : * Diagnosis ganglioneuroma ganglioneuroblastoma intermixed INRG Stage L2 Inclusion criterion : *age ≤ 18 month Exclusion criterion : metastatic site MYCN amplification age &gt; 18 month INRG Stage Ms Inclusion criterion : * age ≤ 12 month Exclusion criterion : bone , pleura/lung and/or CNS metastasis MYCN amplification age &gt; 12 month 2 . INTERMEDIATE RISK STUDY Inclusion criterion whole intermediate risk group : inform consent followup warrant ; group assignment complete within 6 week diagnosis ; prior chemotherapy radiotherapy Tumour material available biological study accord guideline Biopsy proven neuroblastoma confirm National Reference Laboratory ( NRL ) Exclusion criterion whole intermediate risk group : * Diagnosis ganglioneuroma ganglioneuroblastoma intermixed INRG Stage L1 INSS stage 1 : Inclusion criterion : * MYCN amplify Exclusion criterion : MYCN nonamplified INSS stage 2 , 3 , 4 , 4 INRG Stage L2 : Inclusion criterion : Histology : differentiating , poorly differentiate , undifferentiated neuroblastoma ganglioneuroblastoma nodular MYCN nonamplified age &gt; 18 month Exclusion criterion : neuroblastoma NOS MYCN amplification . age ≤ 18 month INRG Stage M : Inclusion criterion : Any histology MYCN nonamplified age ≤ 12 month Exclusion criterion : MYCN amplification age &gt; 12 month 3 . NEONATAL SUPRARENAL MASSES Inclusion criterion : Age le equal 90 day suprarenal mass discover . Suprarenal mass detect ultrasound and/or MRI . The suprarenal mass may cystic and/or solid , IT CAN NOT REACH THE MIDLINE AND MEASURE ≤ 5 CM AT THE LARGEST DIAMETER . No regional involvement : MRI scan show evidence positive ipsi/contralateral lymph node spread outside suprarenal gland . No metastatic involvement . Frozen plasma available . Informed consent . Availability adequate followup Exclusion criterion : Age old 90 day . Suprarenal mass big 5 cm . Regional involvement . Metastatic involvement . Inability undertake mandatory diagnostic study ( biological marker , US , MRI , MIBG ) . Followup guarantee parents/guardians .</criteria>
	<gender>All</gender>
	<minimum_age>90 Days</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>NEUROBLASTOMA , LOW RISK , INTERMEDIATE RISK</keyword>
</DOC>